Oral BIIB122/DNL151 Safely Lowers LRRK2 Activity in Phase 1 Trials

Oral BIIB122/DNL151 Safely Lowers LRRK2 Activity in Phase 1 Trials

293691

Oral BIIB122/DNL151 Safely Lowers LRRK2 Activity in Phase 1 Trials

Treatment with investigational oral therapy BIIB122/DNL151 safely lowered the activity of disease biomarkers that reflect LRRK2 activity, a protein whose mutations are associated with Parkinson’s disease, according to results from two Phase 1 clinical studies. Plans are being put in place to advance the therapy into late-stage clinical testing in Parkinson’s patients later this year. Trial results were presented at the International Association of Parkinsonism and Related Disorders Virtual Congress held May 1–4. Although Parkinson’s does not have a clear…

You must be logged in to read/download the full post.